5 active
/
70 total (since 2015)
0
Phase 1 Active
16 total
3
Phase 2 Active
25 total
0
Phase 3 Active
20 total
2
Phase 4 Active
14 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Tarsus Pharmaceuticals, Inc. 1 1 0
Sol-Gel Technologies, Ltd. 0 3 1
Vyne Therapeutics Inc. 0 4 0
Padagis LLC 0 4 0
Journey Medical Corporation 0 3 0
CAGE Bio Inc. 0 3 0
Maruho Co., Ltd. 0 3 0
Actavis Inc. 0 3 0
NCT05296629 COMPLETED
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
Journey Medical Corporation n=323
NCT05343455 COMPLETED
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
Journey Medical Corporation n=330
NCT02547441 COMPLETED
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
Maruho Co., Ltd. n=463
NCT02576860 COMPLETED
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
Maruho Co., Ltd. n=263
NCT02576847 COMPLETED
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
Maruho Co., Ltd. n=307
NCT03276936 COMPLETED
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
Vyne Therapeutics Inc. n=504
NCT03564119 COMPLETED
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
Sol-Gel Technologies, Ltd. n=372
NCT03564145 TERMINATED
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Sol-Gel Technologies, Ltd. n=547
NCT03448939 COMPLETED
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Sol-Gel Technologies, Ltd. n=361
NCT02800148 COMPLETED
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
Padagis LLC n=667
NCT03352323 COMPLETED
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Padagis LLC n=50
NCT02795117 COMPLETED
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
Padagis LLC n=486
NCT02385240 COMPLETED
Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
Padagis LLC n=552
NCT03954444 COMPLETED
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Actavis Inc. n=1,105
NCT03142451 COMPLETED
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Vyne Therapeutics Inc. n=751
NCT04608500 COMPLETED
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
Vyne Therapeutics Inc. n=771
NCT04106726 COMPLETED
Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea
Zydus Worldwide DMCC n=525
NCT02393937 COMPLETED
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
bioRASI, LLC n=963
NCT03287791 COMPLETED
A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
Actavis Inc. n=924
Data: ClinicalTrials.gov